Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus Pembrolizumab in Metastatic Gastroesophageal Cancer
NCT03321630Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Oct 2017
- Primary completion
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, pembrolizumab in gastroesophageal junction cancer, gastric cancer (GC), sponsored by NYU Langone Health. Started Oct 2017; status: completed.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
gastroesophageal junction cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT03321630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03321630.